MX2023011157A - Peptidos y metodos para reducir la pigmentacion de la piel. - Google Patents

Peptidos y metodos para reducir la pigmentacion de la piel.

Info

Publication number
MX2023011157A
MX2023011157A MX2023011157A MX2023011157A MX2023011157A MX 2023011157 A MX2023011157 A MX 2023011157A MX 2023011157 A MX2023011157 A MX 2023011157A MX 2023011157 A MX2023011157 A MX 2023011157A MX 2023011157 A MX2023011157 A MX 2023011157A
Authority
MX
Mexico
Prior art keywords
methods
peptides
disclosure
skin pigmentation
reducing skin
Prior art date
Application number
MX2023011157A
Other languages
English (en)
Spanish (es)
Inventor
Robert A Love
Original Assignee
Glo Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glo Pharma Inc filed Critical Glo Pharma Inc
Publication of MX2023011157A publication Critical patent/MX2023011157A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14Liposomes; Vesicles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64Proteins; Peptides; Derivatives or degradation products thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/02Preparations for care of the skin for chemically bleaching or whitening the skin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • C07K14/4703Inhibitors; Suppressors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
MX2023011157A 2021-03-24 2022-03-23 Peptidos y metodos para reducir la pigmentacion de la piel. MX2023011157A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163165611P 2021-03-24 2021-03-24
US202163271646P 2021-10-25 2021-10-25
PCT/US2022/021579 WO2022204305A2 (en) 2021-03-24 2022-03-23 Peptides and methods for reducing skin pigmentation

Publications (1)

Publication Number Publication Date
MX2023011157A true MX2023011157A (es) 2024-01-25

Family

ID=83398134

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023011157A MX2023011157A (es) 2021-03-24 2022-03-23 Peptidos y metodos para reducir la pigmentacion de la piel.

Country Status (9)

Country Link
US (2) US12162956B2 (https=)
EP (1) EP4313100A4 (https=)
JP (1) JP2024511214A (https=)
KR (1) KR20240035939A (https=)
AU (1) AU2022242835A1 (https=)
BR (1) BR112023019249A2 (https=)
CA (1) CA3213099A1 (https=)
MX (1) MX2023011157A (https=)
WO (1) WO2022204305A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4034087A4 (en) 2019-09-23 2023-10-25 DDS Research Inc. LIPID VESICLE COMPOSITIONS USING PENETRATION ENHANCING AGENTS
WO2022204305A2 (en) 2021-03-24 2022-09-29 Glo Pharma, Inc. Peptides and methods for reducing skin pigmentation
CN118206619B (zh) * 2024-03-07 2025-08-22 深圳市维琪科技股份有限公司 环九肽及其组合物和用途
CN118440884A (zh) * 2024-03-27 2024-08-06 陕西微泌生物科技有限公司 一种工程化牛奶外泌体的制备方法及其应用

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4372977A (en) 1977-05-31 1983-02-08 Block Drug Company, Inc. Polyoxethylene derivatives as antipruritic ectoparasiticide
US4855090A (en) 1987-03-13 1989-08-08 Micro-Pak, Inc. Method of producing high aqueous volume multilamellar vesicles
MY103673A (en) 1988-01-14 1993-08-28 Kao Corp Detergent composition
DE69425750T2 (de) 1993-07-28 2001-04-26 Pharmaderm Laboratories Ltd., Saskatoon Zweiphasige multilamellare lipidvesikel
US5853755A (en) 1993-07-28 1998-12-29 Pharmaderm Laboratories Ltd. Biphasic multilamellar lipid vesicles
ES2293638T3 (es) 1994-03-25 2008-03-16 Isotechnika, Inc. Mejora de la eficacia de farmacos por deuteracion.
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
FR2730928B1 (fr) 1995-02-23 1997-04-04 Oreal Composition a base de vesicules lipidiques a ph acide et son utilisation en application topique
US5993852A (en) 1997-08-29 1999-11-30 Pharmaderm Laboratories Ltd. Biphasic lipid vesicle composition for transdermal administration of an immunogen
EP2481401A1 (en) 1999-01-18 2012-08-01 LG Life Sciences, Ltd. Lipophilic microparticles containing a protein drug or antigen and formulation comprising same
US6696424B1 (en) 1999-05-28 2004-02-24 Vical Incorporated Cytofectin dimers and methods of use thereof
WO2001030808A1 (en) 1999-10-27 2001-05-03 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor-ligand binding
WO2001035998A1 (en) 1999-11-12 2001-05-25 Pharmaderm Laboratories, Ltd. Compositions for transdermal and transmucosal administration of therapeutic agents
US6656499B1 (en) 1999-11-12 2003-12-02 Pharmaderm Laboratories, Ltd. Composition for transdermal and dermal administration of interferon-α
FR2816577B1 (fr) 2000-11-10 2003-03-21 Peguform France Ensemble pour vehicule comportant un pare-chocs et une piece de carrosserie
US20030083286A1 (en) 2001-08-22 2003-05-01 Ching-Leou Teng Bioadhesive compositions and methods for enhanced intestinal drug absorption
US20030119774A1 (en) 2001-09-25 2003-06-26 Marianna Foldvari Compositions and methods for stimulating an immune response
FR2846238B1 (fr) 2002-10-29 2006-06-23 Oreal Composition sous forme d'emulsion huile-dans-eau et ses utilisations notamment cosmetiques
US20040219232A1 (en) * 2003-02-06 2004-11-04 Zengen, Inc. Methods and compounds for treating malabsorption diseases and inflammatory conditions of the gastrointestinal tract
ATE471340T1 (de) * 2004-02-11 2010-07-15 Amylin Pharmaceuticals Inc Peptide der amylin familie, verfahren zu deren herstellung und verwendung
WO2006012414A2 (en) 2004-07-20 2006-02-02 Critical Therapeutics, Inc. Novel polyadenylation signal for use in expression vectors
FR2876577B1 (fr) 2004-10-15 2007-02-02 Oreal Creme savon a l'alcool behenylique
EA013056B1 (ru) 2005-04-01 2010-02-26 Ньюроджесэкс, Инк. Масла капсаициноидов и способы их получения и применения
NZ565217A (en) * 2005-07-08 2010-03-26 Ipsen Pharma Sas Melanocortin receptor ligands
FR2892939B1 (fr) 2005-11-10 2010-01-22 Groupement Coeur Artificiel Total Carpentier Matra Carmat Materiau hemocompatible composite et son procede d'obtention
EP1955691A1 (en) 2005-11-24 2008-08-13 Shiseido Company, Limited External preparation for skin
KR100748035B1 (ko) 2006-02-22 2007-08-09 (주)아모레퍼시픽 비인지질 베지클로 포집된 유용성분을 함유하는 화장료조성물
AU2007233155B2 (en) 2006-03-29 2012-04-26 Scitech Development Llc Liposomal nanoparticles and other formulations of fenretinide for use in therapy and drug delivery
US20080008747A1 (en) 2006-07-07 2008-01-10 Royds Robert B Transdermal patch
FR2911280B1 (fr) * 2007-01-16 2012-06-22 Mayoly Spindler Lab Association de composes inhibiteurs de la melanogenese et leurs utilisations en cosmetique et en dermatologie
WO2008119160A1 (en) 2007-03-30 2008-10-09 Pharmaderm Laboratories Ltd. Biphasic lipid-vesicle composition and method for treating cervical dysplasia by intravaginal delivery
EP1985298A1 (en) 2007-04-24 2008-10-29 Azad Pharma AG Ophtalmic oil-in-water emulsions containing prostaglandins
FR2921253B1 (fr) 2007-09-26 2012-11-16 Lvmh Rech Composition cosmetique sous la forme d'une emulsion comprenant une phase aqueuse continue et une phase grasse dispersee et son procede de preparation
CA2998948A1 (en) * 2008-05-27 2009-12-17 Genzyme Corporation Peptide analogs of alpha-melanocyte stimulating hormone
US20120014894A1 (en) * 2008-12-31 2012-01-19 Revance Therapeutics, Inc. Compositions and Methods for Treating Hyperpigmentation
US8614185B2 (en) * 2009-05-04 2013-12-24 Centocor Ortho Biotech Inc. Fusion proteins of alpha-MSH derivatives and Fc
UA111147C2 (uk) 2009-11-11 2016-04-11 Байєр Б.В. Способи та композиції для лікування або профілактики зовнішнього отиту
WO2012088414A1 (en) * 2010-12-23 2012-06-28 Ludwig Institute For Cancer Research Ltd. Liposomal formulation of nonglycosidic ceramides and uses thereof
US10159646B2 (en) 2013-08-12 2018-12-25 Altum-Avro Pharma Partnership Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
US20160151283A1 (en) 2014-11-27 2016-06-02 Icnoderm S.R.L. Hyalurosomes, their use in topical cosmetic or pharmaceutical compositions and their preparation process
SG10201506686WA (en) * 2015-08-24 2017-03-30 Agency Science Tech & Res Conjugates
ES3055492T3 (en) 2015-09-16 2026-02-12 Dfb Soria Llc Delivery of drug nanoparticles and methods of use thereof
US20170304232A1 (en) 2016-04-20 2017-10-26 Northwestern University Endoxifen For Local Transdermal Therapy To The Breast
US10324135B2 (en) 2016-06-06 2019-06-18 Mitsubishi Electric Research Laboratories, Inc. Methods and systems for data-driven battery state of charge (SoC) estimation
WO2018144093A2 (en) 2016-11-03 2018-08-09 Pinsky Mark A Formulations for improved skin care
US11117930B2 (en) 2017-02-23 2021-09-14 Adrx, Inc. Peptide inhibitors of transcription factor aggregation
US10251709B2 (en) 2017-03-05 2019-04-09 Samuel Cho Architecture, system, and method for developing and robotically performing a medical procedure activity
WO2018170196A1 (en) 2017-03-15 2018-09-20 Dfb Soria, Llc Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes
US20180360757A1 (en) 2017-05-26 2018-12-20 Altum Pharmaceuticals Inc. Biphasix cannabinoid delivery
WO2019168163A1 (ja) 2018-03-02 2019-09-06 国立大学法人広島大学 形質転換体および当該形質転換体を用いた還元型リン化合物の有無の検出方法
CN108948151B (zh) * 2018-08-06 2019-06-21 山西锦波生物医药股份有限公司 肽及其制备方法和用途
EP3866828A4 (en) 2018-10-16 2022-08-31 GLO Pharma, Inc. Nicotinic acetylcholine receptor peptide antagonist conotoxin compositions and related methods
EP4034087A4 (en) 2019-09-23 2023-10-25 DDS Research Inc. LIPID VESICLE COMPOSITIONS USING PENETRATION ENHANCING AGENTS
US20230149560A1 (en) 2020-04-20 2023-05-18 Massachusetts Institute Of Technology Lipid compositions for delivery of sting agonist compounds and uses thereof
WO2022204305A2 (en) 2021-03-24 2022-09-29 Glo Pharma, Inc. Peptides and methods for reducing skin pigmentation
CA3212844A1 (en) 2021-03-24 2022-09-29 Marianna Foldvari Multisome lipid vesicles for delivery of cosmetic agents
AU2022245251A1 (en) 2021-03-24 2023-10-12 Glo Pharma, Inc. Multisome lipid vesicles for delivery of cosmetic agents
WO2022204309A1 (en) 2021-03-24 2022-09-29 Twist Bioscience Corporation Variant nucleic acid libraries for tigit
KR20240102989A (ko) 2021-11-04 2024-07-03 글로 파마, 인크. 화장품 적용을 위한 방법 및 조성물

Also Published As

Publication number Publication date
US20250026787A1 (en) 2025-01-23
KR20240035939A (ko) 2024-03-19
US12162956B2 (en) 2024-12-10
WO2022204305A2 (en) 2022-09-29
US20240190917A1 (en) 2024-06-13
EP4313100A2 (en) 2024-02-07
BR112023019249A2 (pt) 2023-12-12
JP2024511214A (ja) 2024-03-12
EP4313100A4 (en) 2025-10-15
CA3213099A1 (en) 2022-09-29
WO2022204305A3 (en) 2022-11-17
AU2022242835A1 (en) 2023-10-05

Similar Documents

Publication Publication Date Title
MX2023011157A (es) Peptidos y metodos para reducir la pigmentacion de la piel.
EP4349360A3 (en) Peptide exhibiting wrinkle-improving activity and uses thereof
MX2017007819A (es) Compuestos peptidicos, composiciones que los comprenden y usos de esos compuestos, en particular usos cosmeticos.
MX2021004296A (es) Composiciones de conotoxina del antagonista del peptido receptor nicotinico de acetilcolina y metodos relacionados.
MX2014001318A (es) Composiciones para el cuidado de la piel que contienen combinaciones de ingredientes naturales.
EP3272329A3 (en) Compositions and methods for stimulation magp-1 to improve the appearance of skin
NZ626945A (en) Chimeric factor viii polypeptides and uses thereof
CA2596597A1 (en) Method for stimulation collagen synthesis and/or kgf expression
AR096162A1 (es) Péptidos terapéuticos
MX377317B (es) Compuestos de hormona de crecimiento humana recombinante unidos a peg.
ATE442064T1 (de) Make-up-kit und -verfahren
WO2008082736A3 (en) Compositions and methods of their use for improving the condition and appearance of skin
PH12018500619A1 (en) A skin lightening composition comprising niacinamide and its isomers
EP4306123A3 (en) Saposin-a derived peptides and uses thereof
WO2018231988A3 (en) COSMETIC COMPOSITIONS AND METHODS FOR USE IN SKIN REFRESH
EA202092820A1 (ru) Композиция для расслабления мышц
MY209392A (en) Use of amino acid supplementation for improved muscle protein synthesis
KR20140140396A (ko) 피부 주름 개선 및 미백용 조성물
EP4289412A3 (en) Topical skin formulations
KR101814049B1 (ko) 펩타이드를 유효성분으로 함유하는 피부 미백용 화장료 조성물
WO2012092350A3 (en) Topical uses szeto-schiller peptides
AR059638A1 (es) Composiciones contentivas de peptidos con aminoacidos no naturales y metodos de uso
CA2624990A1 (en) Ckrox peptides and analogs thereof for treating skin ageing
MY193527A (en) Conjugate of minoxidil and peptide
CN107405278A8 (zh) 序列为his‑d‑trp‑ala‑trp‑d‑phe‑lys‑nh2的肽用于减少或延缓细胞衰老的出现和皮肤老化的迹象的新型用途